Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:9953 |
| Name | acute biphenotypic leukemia |
| Definition | An acute leukemia that is characterized by the occurrence of more than one type of leukemia at the same time resulting from either the occurrence of blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute biphenotypic leukemia |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| NRAS Q61R | Trametinib | acute biphenotypic leukemia | no benefit | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02091245 | Phase I | Selinexor | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | Active, not recruiting | USA | 0 |
| NCT03326921 | Phase I | Cyclophosphamide + Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |
| NCT03643276 | Phase III | Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Mercaptopurine + Methotrexate Bortezomib + Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Pegaspargase + Vincristine Sulfate + Vindesine Blinatumomab + Cyclophosphamide + Cytarabine + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab Cytarabine + Daunoxome + Fludarabine + Methotrexate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Mercaptopurine + Methotrexate Asparaginase Erwinia chrysanthemi Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | Recruiting | SVK | ITA | ISR | DEU | CZE | CHE | AUT | AUS | 0 |
| NCT03957915 | Phase I | INA03 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03) | Completed | FRA | 0 |
| NCT04334993 | Phase II | Blinatumomab | Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | Unknown status | ISR | 0 |
| NCT04501614 | Phase Ib/II | Ponatinib | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Terminated | USA | POL | NLD | ITA | GBR | FRA | ESP | CZE | BRA | AUS | ARG | 4 |
| NCT04797767 | Phase Ib/II | Cladribine + Cytarabine + Mitoxantrone + Sargramostim + Venetoclax | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | Recruiting | USA | 0 |
| NCT04827745 | Phase II | Blinatumomab | Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL | Completed | USA | 0 |
| NCT04872478 | Phase I | MRX-2843 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults with Relapsed/Refractory AML, ALL, or MPAL | Recruiting | USA | 0 |
| NCT04964518 | Phase I | APG-2575 + Azacitidine | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Unknown status | USA | AUS | 0 |
| NCT05038644 | Phase I | XmAb18968 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | Terminated | USA | 0 |
| NCT05101551 | Phase I | Gemcitabine + Talazoparib + Topotecan | Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy (PARPAML) | Recruiting | USA | 0 |
| NCT05110742 | Phase Ib/II | CAR.5/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | Active, not recruiting | USA | 0 |
| NCT05146739 | Phase I | Cytarabine + Fludarabine + Uproleselan | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane | Active, not recruiting | USA | 0 |
| NCT05292664 | Phase I | Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax | Venetoclax Basket Trial for High Risk Hematologic Malignancies | Active, not recruiting | USA | 0 |
| NCT05326516 | Phase I | Revumenib | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | Completed | USA | CAN | 0 |
| NCT05327894 | Phase III | Blinatumomab | Interfant-21 Treatment Protocol for Infants Under 1 Year with KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21) | Active, not recruiting | SWE | SVK | NOR | NLD | LTU | ITA | IRL | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG | 3 |
| NCT05360160 | Phase Ib/II | Decitabine and Cedazuridine Revumenib Venetoclax | A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | Recruiting | USA | 0 |
| NCT05476770 | Phase I | Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Recruiting | USA | AUS | 0 |
| NCT05761171 | Phase II | Cytarabine + Fludarabine Pegaspargase + Prednisone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisone + Vincristine Sulfate Revumenib Cytarabine + Hydrocortisone + Methotrexate Pegaspargase + Prednisolone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisolone + Vincristine Sulfate | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | Active, not recruiting | USA | CAN | 0 |
| NCT05848687 | Phase Ib/II | Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone | TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II | Recruiting | USA | CAN | 0 |
| NCT05918692 | Phase I | BMF-500 | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | Active, not recruiting | USA | 0 |
| NCT06390319 | Phase II | Cyclophosphamide + Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Bortezomib + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Bortezomib + Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Venetoclax + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Thioguanine Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Vincristine Sulfate | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | Recruiting | USA | 0 |
| NCT06397027 | Phase I | Azacitidine + Venetoclax + Ziftomenib | A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias | Recruiting | USA | 0 |
| NCT06448013 | Phase I | Gemtuzumab ozogamicin + Venetoclax + Ziftomenib | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
| NCT06466395 | Phase I | Cyclophosphamide + Dexamethasone + Doxorubicin + Venetoclax + Vincristine Sulfate | A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias | Recruiting | USA | 0 |
| NCT06474663 | Phase I | Cladribine + Cytarabine + Decitabine + Sorafenib | A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias | Withdrawn | 0 | |
| NCT06522373 | Phase I | TAK-169 | Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease | Withdrawn | 0 | |
| NCT06769490 | Phase I | Quizartinib + Ziftomenib | Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia | Recruiting | USA | 0 |
| NCT07052994 | Phase I | Cytarabine + Doxorubicin + Gemtuzumab ozogamicin + Revumenib | A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients | Not yet recruiting | USA | 0 |
| NCT07222579 | Phase II | Blinatumomab | Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) | Not yet recruiting | USA | 0 |